The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients
NCT06496009
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
845
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
PD-1 Inhibitors
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China